Covid-19 Testing Continues To Be A Pressing Issue
Bio Spectrum|June 2020
One of the key constraints for Indian researchers and manufacturers to develop quickly testing kits in the country is dependency for raw materials such as enzymes, antigens, antibodies etc., required for research and manufacturing. All this is leading to delays in development of high quality and affordable testing solutions. Government should provide necessary support to develop the “ancillary” support for the researchers and manufacturers so that India can become self-reliant.
Dr P. Siva Kumar
Covid-19 Testing Continues To Be A Pressing Issue

The World Health Organisation (WHO) has recommended that each country assess its risk and rapidly implement the necessary measures and prepare for a testing and clinical care surge to reduce COVID-19 transmission. Diagnostic testing will enable mitigation of COVID-19 virus spread and will facilitate achieving a level of preparedness and responsiveness to effectively identify, manage and care for new cases of COVID-19. The need for universal and massive testing across the population has, therefore, led to a race for technology innovations for COVID-19 diagnosis.

However, there have been several challenges with respect to the quality of certain types of tests and supply chain issues. Hopefully, as the days pass by, the situation could improve and stabilize.

Given that the virus is new, and the tests are still very new to the scene, it is important to note that the true clinical sensitivity is unknown. Therefore, the accuracy of results from the technologies that are available may not be of the desired levels. It is essential that aggressive research work is undertaken to enable the development of more accurate and reliable technologies.

As most of us are aware, by now, RT-PCR technology detects the virus while it is circulating in the body and enables diagnosis of the disease for appropriate treatment. RT-PCR test aids the identification of individuals who are infected, the management of patients, and implementation of mitigation strategies for preventing the spread of the disease.

Denne historien er fra June 2020-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra June 2020-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIO SPECTRUMSe alt
Sartorius Stedim Biotech opens new centre for bioprocess innovation in US
Bio Spectrum

Sartorius Stedim Biotech opens new centre for bioprocess innovation in US

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.

time-read
1 min  |
BioSpectrum India Jan 2025
Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research
Bio Spectrum

Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research

Agilent Technologies Inc. has announced the new MitorOCR Assay Kit.

time-read
1 min  |
BioSpectrum India Jan 2025
Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data
Bio Spectrum

Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data

Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.

time-read
1 min  |
BioSpectrum India Jan 2025
Parse Biosciences announces expansion of Evercode BCR product line
Bio Spectrum

Parse Biosciences announces expansion of Evercode BCR product line

Parse Biosciences, a leader in scalable single cell sequencing solutions, has announced the expansion of its Evercode BCR product line to enable applications in mice.

time-read
1 min  |
BioSpectrum India Jan 2025
New technology for unambiguous detection of HIV genome using tailored fluorogenic tests
Bio Spectrum

New technology for unambiguous detection of HIV genome using tailored fluorogenic tests

A team of scientists at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has developed a novel diagnostic technology known as the GQ Topology-Targeted Reliable Conformational Polymorphism (GQ-RCP) platform.

time-read
1 min  |
BioSpectrum India Jan 2025
Gene mutation likely cause for developing autism in early childhood: RGCB study
Bio Spectrum

Gene mutation likely cause for developing autism in early childhood: RGCB study

Autism, a developmental disorder that causes functional abnormalities in brain development, is caused by a combination of environmental and genetic factors with its symptoms manifesting in childhood as early as the age of two years.

time-read
1 min  |
BioSpectrum India Jan 2025
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
Bio Spectrum

IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing

A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing.

time-read
1 min  |
BioSpectrum India Jan 2025
RSSDI study lays focus on Yoga and Diabetes Prevention
Bio Spectrum

RSSDI study lays focus on Yoga and Diabetes Prevention

Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, recently released the landmark study by Research Society for Study of Diabetes in India (RSSDI) on 'Yoga and Diabetes Prevention'.

time-read
1 min  |
BioSpectrum India Jan 2025
Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare
Bio Spectrum

Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare

RJ Corp Healthcare, a leading name in the healthcare sector through its renowned entities Cocoon Hospital and Cryoviva Stem Cell Bank, has announced the appointment of Dr Alok Khullar as Group Chief Executive Officer (CEO).

time-read
1 min  |
BioSpectrum India Jan 2025
Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser
Bio Spectrum

Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser

Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser.

time-read
1 min  |
BioSpectrum India Jan 2025